Skip to main content
SpringerLink
Log in

Response to the letter from Dr. Veerman and colleagues

  • Letter to the Editor
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Choi KH, Wykes T, Kurtz MM (2013) Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry 203:172–178

    Article  PubMed  PubMed Central  Google Scholar 

  • Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301–307

    Article  PubMed  Google Scholar 

  • Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. In: collaboration TC (ed) http://handbookcochrane.org

  • Iwata Y, Nakajima S, Suzuki T, Keefe RS, Plitman E, Chung JK, Caravaggio F, Mimura M, Graff-Guerrero A, Uchida H (2015) Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry 20:1151–1160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535

    Article  PubMed  PubMed Central  Google Scholar 

  • Veerman SR, Schulte PF, Smith JD, de Haan L (2016) Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol Med 46(9):1909–21

  • Veerman SR, Schulte PF, Deijen JB, de Haan L (2017) Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. Psychol Med 47:363–375

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. S. R. T. Veerman (Mental Health Service Organization North Holland North, Community Mental Health Division, Flexible Assertive Community Treatment, Alkmaar, The Netherlands) and Dr. David de Lucena (rograma de Pós-Graduação, em Medicina: Psiquiatria, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil) for providing information for this study.

Funding

No grant support or other sources of funding were used to conduct this study or prepare this manuscript.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Department of Psychiatry, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan

    Taro Kishi, Yuki Matsuda & Nakao Iwata

  2. Department of Communication Sciences and Disorders, School of Applied Sciences, University of Mississippi, University, MS, 38677, USA

    Toshikazu Ikuta

  3. Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8551, Japan

    Yuki Matsuda

Authors
  1. Taro Kishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshikazu Ikuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuki Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nakao Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The manuscript was written by all authors. Dr. Iwata supervised the review.

Corresponding author

Correspondence to Taro Kishi.

Ethics declarations

Conflict of interest

Drs. Kishi, Ikuta, Matsuda, and Iwata declare that they have no direct conflicts of interest relevant to this study. Dr. Kishi has received a speaker’s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Janssen, Otsuka, Meiji, MSD, Tanabe-Mitsubishi (Yoshitomi), and Pfizer, and has a Health Labor Sciences Research Grant and a Fujita Health University School of Medicine research grant.

Dr. Ikuta has received speaker’s honoraria from Eli Lilly, Daiichi Sankyo, and Dainippon Sumitomo.

Dr. Matsuda has received speaker’s honoraria from Dainippon Sumitomo, Eisai, Eli Lilly, GlaxoSmithKline, Otsuka, Tanabe-Mitsubishi and Pfizer, and has a Grant-in-Aid for Young Scientists (B).

Dr. Iwata has received speaker’s honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer, and had research grants from GlaxoSmithKline, Meiji, and Otsuka.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kishi, T., Ikuta, T., Matsuda, Y. et al. Response to the letter from Dr. Veerman and colleagues. Psychopharmacology 234, 3537–3538 (2017). https://doi.org/10.1007/s00213-017-4757-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-017-4757-8

Search

Navigation